Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thyroid Biological Toxicity and Tumor Response in Patients Treated With NIVOLUMAB 2nd Line in Non-small Cell Bronchopulmonary Cancer

NCT04470440 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT04470440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04470440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thyroid Biological Toxicity and Tumor Response in Patients Treated With NIVOLUMAB 2nd Line in Non-small Cell Bronchopulmonary Cancer
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Completed
Start date
October 22, 2019
Completion date
November 5, 2019
Enrollment
134 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitor, non small cell lung cancer metastatic, prognosis, thyroid dysfunction, treatment adverse effect